June 10, 2016
A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY)
- Study Sponsor: Eiger BioPharmaceuticals, Inc.
- Institution: Eiger BioPharmaceuticals, Inc.
- Start Date: April, 2016
- End Date: Completed
- Design: Placebo-controlled
Background treatment allowed
- Age range (years): from 18 to 75
- Type of PH
- Study Duration for individual patient: 24 weeks
- Contact: Company Website: www.eigerbio.com; Contact info about trial: Erica McCluskey (email@example.com)
- Listing on clinicaltrials.gov